The CO-PILOT trial is the first RCT comparing AHCL with standard diabetes care (multiple daily injections [MDI] and CSII) to test our hypothesis that AHCL will improve glucose control and reduce burden of care in children and youth with suboptimal glycemia naïve to AHCL and struggling to achieve recommended glycemic targets with traditional insulin therapies. Here, INS is linked to diabetes mellitus.